Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...

People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than ...

Some people using GLP-1 drugs like Ozempic for weight loss have a problem: Eggs are suddenly expensive and hard to find. Eggs aren't just big with fitness fans and Gaston from "Beauty and the Beast." ...

By Gina Kolata The idea was so tantalizing. Drugs in the GLP-1 class, which includes Wegovy and Ozempic, have proved miraculous in treating weight loss and other diseases. And some researchers ...

A comprehensive new study confirmed that GLP-1 medications such as Ozempic and Mounjaro have myriad health benefits — even more than previously thought. Analyzing the medical records of roughly ...

By Dani Blum The Food and Drug Administration on Tuesday approved Ozempic to reduce the risk of serious complications in people who have both Type 2 diabetes and chronic kidney disease.

Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney ... more than 1,000 non-dialysis CKD charts shows nephrologists were turned ...

Scientists remain puzzled as to why some people taking popular weight loss and diabetes medications like Ozempic and Wegovy are losing their vision suddenly, highlighting that there's still so ...

Are you a print subscriber? Activate your account. By Ad Age Staff - 2 hours 11 min ago By Ad Age and Creativity Staff - 2 hours 28 min ago By Jack Neff - 3 hours 14 min ago 4 hours 25 min ago 6 ...

Off-lable weight-loss drugs such as Ozempic have been a breakthrough because they eliminate the need to cut back or compensate by mimicking the gut hormone (GLP-1) and making people feel full faster.

Oprah Winfrey said taking weight-loss drugs, like Ozempic and Wegovy, helped her realize the truth about 'thin people.' In 2023, the media mogul, 70, finally admitted to using an undisclosed GLP-1 ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Another busy day, so let’s get straight into the news ...